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The aim of this thesis is to investigate the pharmacokinetics and toxicity of the novel oral 
demethylating agent zebularine (zeb) in laboratory dogs and tumor bearing dogs.  This 
thesis focuses on the application of this therapeutic strategy in dogs with naturally 
occurring invasive transitional cell carcinoma (InvTCC), which serve as a relevant model 
of the human disease. 
 
DNA hypermethylation in the promoter region is a common epigenetic change in cancer 
that silences tumor suppressor genes.  Zeb is an oral cytidine analog that acts as a 
demethylating agent.  Zeb has been investigated extensively in vitro as well as in mice, 
rodents and rhesus monkeys.  Prior to the investigation described in this thesis, zeb had 
not been investigated in the dog.  The authors set out to investigate zeb in dogs with 
naturally occurring InvTCC with an eventual goal of applying this treatment strategy to 
humans with this devastating cancer. 
  
The first part of this thesis reviews the importance of DNA methylation in cancer 




and the application of demethylating agents in InvTCC in the dog.  The second part of 
this thesis presents initial pharmacokinetics and toxicity data following high dose oral zeb 
in laboratory dogs (n=3) and tumor bearing dogs (n=3).  Daily high dose oral zeb at 4 mg 
kg-1 resulted in remarkable, but reversible, hematologic toxicity in the form of 
neutropenia in laboratory dogs.  Dose adjustment revealed that a dose intensity of 4 mg 
kg-1 once every 21 days was well tolerated in tumor bearing dogs.  The third part of this 
thesis presents the results to date of a phase I dose escalation trial of oral zeb in 26 dogs 
with InvTCC.  At daily doses up to 0.5 mg kg-1, zeb was well tolerated.  At higher doses, 
dose-limiting toxicity (DLT) was detected.  In a population in which 73% of dogs had 
failed previous treatment, overall disease control rate of 73.3% was detected, and median 
progression free survival time was 86 days (95% CI, 47.5-124.5).  Of particular interest is 
that one dog has experienced disease stabilization for more than 511 days. 
 
Remarkable, but reversible, neutropenia was detected in laboratory dogs treated with high 
dose daily zeb.  Low dose daily zeb at doses up to 0.5 mg kg-1 was well tolerated in dogs 
with InvTCC.  Initial results indicate promising disease control rates and progression free 
survival in a population of dogs that was heavily pretreated.  These results warrant further 
investigation as a treatment strategy in dogs with InvTCC with potential applications to 
the human disease.  Further investigation is required to determine if the optimal effects of 
zeb may be in combination with cytotoxic chemotherapy drugs and to document that 




CHAPTER 1.  INTRODUCTION 
1.1 Introduction 
Epigenetic changes are heritable changes that alter gene expression without 
changing the DNA sequence.1,2  DNA methylation is one of the most studied epigenetic 
changes in mammals.  DNA methylation may become dysregulated due to altered DNA 
methyltransferase (DNMT) activity and other changes associated with chronic 
inflammation and exposure to carcinogens.1  DNA methylation in mammals occurs on 
cytosine residues in the 5’ position to guanine residues in a cytosine guanine dinucleotide 
(CpG).2,3 
CpGs are unevenly distributed throughout the genome and are concentrated 
within short repeats called CpG islands.3  These CpG islands are concentrated within the 
promoter regions of half or more of all mammalian genes.2,3  In normal cells, promoter 
region CpG islands are usually unmethylated, whereas in cancer cells, these regions are 
often hypermethylated.  Hypermethylation of promoter region CpG islands results in 
transcriptional silencing.3  Hypermethylation of DNA within a gene promoter region 
prevents binding of the transcriptional apparatus by physically blocking its interaction 
with DNA.1  Methylation attracts methyl-CpG binding proteins which attract histone and 
chromatin remodeling complexes that alter the conformation of chromatin from the 





DNA methylation is mediated by DNMTs.3,4  DNMTs are responsible for 
establishing and maintaining the patterns of methylation throughout DNA synthesis.4  
DNMTs transfer methyl groups from S-adenosyl-l-methionine to CpGs as DNA is 
replicated during S-phase.1,4  When the CpG on one daughter strand pairs with a CpG 
on the complementary strand of DNA, the resultant pair can be unmethylated, 
partially methylated (hemi-methylated) or completely methylated.  DNMT1 
preferentially binds to partially methylated CpG pairs, restoring a completely 
methylated state.4  DNMT1 is largely responsible for maintenance methylation, while 
DNMT3a and DNMT3b are responsible for de novo methylation.2,3,5  De novo 
methylation is associated with aging and inflammation, and likely occurs early in 
tumor development.3  Expression of DNMT3a and 3b is high during embryogenesis, 
and low in adult cells.2  Expression of DNMT is essential to development as indicated 
by the fact that mice deficient in either DNMT1 or DNMT3b are embryonic lethal, 
and mice deficient in DNMT3a die before they are 4 weeks old.2 
Tumor suppressor gene function can be lost due to hypermethylation of gene 
promoter regions, mutations and DNA loss through deletions.4  DNA 
hypermethylation is frequently the “second hit” in familial cancers, leading to gene 
inactivation.3  Transcriptional silencing by promoter hypermethylation has been 
demonstrated in important genes involved in apoptosis, DNA repair, cell cycle 
regulation, metastasis/invasion and hormone receptors.2,3  The list of human genes 
that have been documented as silenced through DNA methylation include ATM 
(ataxia telangiectasia mutated), APC (adenomatosis polyposis coli), BRCA2 (breast 





inhibitor 2A), GSTP1 (glutathione S-transferase pi), P14ARF, P15, P16INK4A PTEN 
(phosphatase and tensin homologue), RASSF1A (Ras association domain containing 
protein 1a) RB1 (retinoblastoma 1) and TIMP3 (tissue inhibitor of metalloproteinase 
3).3 
DNA hypermethylation can also contribute to genomic instability and tumor 
progression by promoting genetic mutation.2,3  Silencing of MLH1 (mutL homologue 
1), a mismatch repair gene, is often seen in colon and endometrial cancers with 
microsatellite instability.  Hypermethylation of MLH1 has also been demonstrated 
within adjacent normal colonic epithelium of people with colon cancer, and 
hyperplastic tissue in people with endometrial cancer.3  Hypermethylation of MGMT 
(O6-methylguanine-DNA methyltransferase), a gene that repairs carcinogen induced 
DNA adducts, has been detected in a variety of malignancies, and may facilitate 
mutations in p53 and K-RAS.1,3 
Unlike genetic mutations, DNA methylation is a potentially reversible 
heritable change.2,3,6  There are currently two Food and Drug Administration 
approved injectable demethylating agents in use for the treatment of human 
myelodysplastic syndrome, 5-azacytidine (Vidaza®, Celgene Corp., Summit, NJ, 
USA; 5-Aza-CR) and decitabine (Dacogen®, SuperGen, Inc., Dublin, CA, USA; 5-
Aza-CDR).1  5-Aza-CR has been investigated in dogs with invasive transitional cell 
carcinoma (InvTCC), resulting in 22% partial remission and 50% stable disease for 
more than 8 weeks.  Since demethylating agents function by interfering with the 
activity of DNMTs during DNA replication, continuous exposure in the form of daily 





Zebularine (1-β-D-Ribofuranosyl-2(1H)-pyrimidinone; zeb) is another 
demethylating agent that is very similar in structure to 5-Aza-CR and 5-Aza-CDR, 
but it is stable under a wide range of conditions and can be administered orally.6,8  
The purpose of this work is to describe initial results of investigation of zeb in the dog 
including initial pharmacokinetics and toxicity in laboratory and tumor bearing dogs, 
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CHAPTER 2.  LITERATURE REVIEW 
2.1 Introduction 
This chapter will begin with a review of the available literature on zebularine’s (zeb) 
mechanisms of action as a cytidine deaminase (CDA) inhibitor, DNA methyltransferase 
(DNMT) inhibitor and radiosensitizer.  Then, this chapter reviews zeb’s activity in vivo 
and in vitro and its pharmacokinetics in rodents and monkeys.  Finally, this chapter 
provides an introduction to human and canine invasive transitional cell carcinoma 
(InvTCC), and the basis for the application of demethylating therapy in this disease.   
 
2.2 Zebularine 
Zeb is the 4-desamino analog of cytidine.1-4  Zeb was first synthesized in 1961.3  
Zeb was originally identified as a bacteriostatic drug, then determined to be a potent 
CDA inhibitor and more recently determined to be a DNMT inhibitor.3-5  In addition, zeb 
acts as a radiosensitizer.6,7  Zeb’s physical characteristics make it ideal for oral 
administration.  Zeb has a half-life of 44 hours at 37°C in phosphate buffered saline at pH 
1.0, and 508 hours at pH 7.0.2  The triazine ring of 5-azacytidine (Vidaza®, Celgene 
Corp., Summit, NJ, USA; 5-Aza-CR) and decitabine (Dacogen®, SuperGen, Inc., Dublin, 
CA, USA; 5-Aza-CDR) rapidly decompose even at neutral pH.3  Unlike 5-Aza-CR and 5-





range and is not subject to rapid inactivation by CDA.3,4  The stability of zeb over a 
broad pH range allows for oral administration, unlike 5-Aza-CR and 5-Aza-CDR.2  
While zeb has not been demonstrated to be as potent as 5-Aza-CR or 5-AZa-CDR in 
vitro or in vivo, its stability and reported lack of toxicity allows for chronic or 
continuous administration.3  Once incorporated into DNA, zeb is as potent as 5-Aza-
CR.5 
 
2.3 Zebularine inhibits the activity of cytidine deaminase 
After zeb’s initial synthesis, it was determined to be an inhibitor of CDA.3,4,8,9  
CDA is normally involved in the pyrimidine salvage pathway and converts cytidine 
and deoxyctidine to uridine and deoxyuridine.  CDA is important in the metabolic 
disposition of nucleoside analogs including cytosine arabinoside and 5-Aza-CDR.  
CDA rapidly deaminates cytosine arabinoside and 5-Aza-CDR, resulting in their 
inactivation.4,9 
Unlike other nucleoside analogs, zeb is not subject to deamination by CDA, 
but rather inhibits the enzyme’s activity.  Zeb can enhance the activity of 5-Aza-CDR 
and cytosine arabinoside by inhibiting their CDA mediated degradation.4,8,  The 
combination of zeb and either cytosine arabinoside or 5-Aza-CDR resulted in 
improved survival in tumor bearing mice with L1210 or P388 leukemia.3  
Upregulation of CDA occurs in relapsed leukemias, and can be an important 






2.4 Zebularine is incorporated into DNA and inhibits DNMTs 
Cytidine analogs are incorporated into DNA in place of cytosine residues.1  
Once incorporated into DNA, zeb forms a complex with DNMTs, thus inhibiting 
methylation.  The mechanism of action of zeb’s demethylating activity is essentially 
identical to 5-Aza-CR and 5-Aza-CDR.1,4,10  The target for DNMTs is normally the 
second cytosine base in a GCGC sequence.  Normally, a cytosine base undergoes 
methylation at the 5’ position when it rotates out of the DNA helix through a process 
called base flipping.1,3  When zeb rotates out of the DNA helix, a covalent bond 
forms between the zeb incorporated DNA and the DNMT, resulting in a stable 
nucleoprotein complex.1   
As these zeb-DNA-DNMT complexes form throughout the genome, DNMTs 
are sequestered and depleted, resulting in decreased DNMT activity.11  Following zeb 
treatment, DNMT1’s activity is decreased first.  In vitro, the activity of DNMT1 is 
frequently completely inhibited.  The activity of DNMT3b and then DNMT3a are 
also decreased, but not as robustly.  A lack of change in DNMT RNA transcripts 
following zeb treatment supports that zeb’s mechanism of action is sequestration of 
DNMT in stable nucleoprotein complexes.3 
Activation of zeb is complicated and inefficient.  Zeb must undergo 
phosphorylation and conversion into its deoxynucelotide before it can be incorporated 
into DNA.3,4  Zeb is converted to 2’-deoxyzebularine-5’monophosphate (dZMP), 2’-
deoxyzebularine-5’diphosphate (dZDP), 2’-deoxyzebularine-5’triphosphate (dZTP),  
2’-deoxyzebularine-5’diphosphocholine (ZDP-chol) and 2’-deoxyzebularine-





common, but only the triphosphate dZTP can be incorporated into DNA.  The rate 
limiting step in the zeb’s activation and incorporation into DNA is the conversion of 
zebularine-5’diphosphate to dZDP via ribonucleotidediphosphate reductase.  Up to 
sevenfold more zeb is incorporated into RNA than DNA.3 
 
2.5 Zebularine is preferentially incorporated into tumor cells compared to normal 
fibroblasts 
One concern with the use of demethylating agents is the induction of global 
genome hypomethylation, which has been associated with cancer and genomic 
instability.1,10  While demethylation of the hypermethylated promoter region of a 
tumor suppressor gene would be beneficial in cancer therapy, removing repressive 
methylation from the promoter region of a proto-oncogene within a tumor could have 
deleterious results.1  Interestingly, zeb appears to be preferentially incorporated into 
the DNA of human tumor cells compared to normal human fibroblasts in vitro.10 
Zeb’s activity was investigated in seven human cancer cell lines (T24, HCT15, 
CFPAC-1, SW-48, HT-29, PC3 & CALU-1) and four normal human fibroblast cell 
lines (LD98, T-1, LD419 & CCDD-1070Sk).  Following continuous treatment with 
1,000 µM zeb, the doubling time increased in all seven cancer cell lines.  The cancer 
cell lines appeared to be more susceptible to the affects of zeb than normal fibroblasts.  
Doubling times increased from 33 to 68% in the tumor cell lines and by 12 to 21% in 
fibroblast cell lines.  A two- to sevenfold increase in p21, which encodes a protein 





detected in the cancer cell lines following zeb treatment.  No significant changes in 
p21 were detected in fibroblasts.10 
Promoter methylation resulting in transcriptional silencing of p16 was known 
to be present in all seven cancer cell lines, while normal p16 was present in the 
fibroblast cell lines.  Following 1,000 µM zeb treatment, p16 mRNA levels remained 
unchanged in human fibroblasts, but p16 was induced in five cancer cell lines (T24, 
HCT15, CFPAC-1, SW48 and HT-29).  With continued zeb treatment, p16 
expression was induced in a sixth cancer cell line (CALU-1).  The growth inhibitory 
affects of zeb appear to be due to a combination of upregulation of p21 in all seven 
cell lines and induction of p16 in five of the cell lines.10 
Levels of DNMT1 were evaluated and determined in all seven cancer cell 
lines and human fibroblasts.  DNMT1 activity was decreased in the normal 
fibroblasts and two cancer cell lines (PC3 and CALU-1), but residual activity was still 
present.  Levels of DNMT1 were almost completely depleted in T24, HCT-15, 
CFPAC-1, SW48 and HT-29 cell lines.  DNMT1 mRNA levels were unchanged, 
supporting that depletion occurred due to sequestration of DNMT within zeb-DNA-
DNMT complexes.  Zeb’s growth inhibitory effects were not as great in the cancer 
cell lines that did not have complete depletion of DNMT1 (PC3 and CALU-1) and 
normal human fibroblasts.10  Overall, cancer cells were more susceptible to zeb 
induced growth inhibition, and DNMT1 was almost completely inhibited in five of 
the cell lines. 
Differences in zeb’s activity in cancer cells compared to normal cells may be 





zeb phosphorylation, which is necessary for zeb activation and incorporation into 
DNA.  The activity of uridine/cytidine kinase was three to 40 times greater in cancer 
cell lines compared to human fibroblasts.  The fact that CALU-1, a cancer cell line 
that was resistant to zeb, had low uridine/cytidine kinase activity supports that this 
pathway is important in responsiveness to zeb.  The uridine/cytidine kinase pathway 
likely regulates how much zeb is eventually incorporated into DNA and this enzyme 
is more expressed in many cancer cell lines compared to normal fibroblasts.10  The 
potential for sparing normal tissues is a significant advantage, and may allow for 
accumulation of zeb within tumor tissues while avoiding toxicity to normal cells.  
 
2.6 Zebularine is a radiosensitizer 
Dote et al. investigated zeb’s influence on DNA methylation and 
radiosensitivity in human cell lines from histologies that are normally treated with 
radiation therapy including MiaPaCa (pancreatic carcinoma), U251 (glioblastoma) 
and DU145 (prostate carcinoma).  Methylation-specific polymerase chain reaction 
was used to detect methylation of RASSF1A, HIC-1 and 14-3-3σ, three genes that are 
frequently methylated in human cancers.  All three genes were methylated in 
MiaPaCa and U251 cell lines.  RASSF1A was methylated, HIC-1 was partially 
methylated and 14-3-3σ was unmethylated in the DU145 cell line.6   
Following treatment with zeb for 48 hours at 200 µM (MiaPaCa) and 300 µM 
(U251 and DU145), increased unmethylated RASSF1A and HIC-1 were detected in all 
three cell lines, and unmethylated 14-3-3σ was detected in MiaPaCa and U251 tumor 





and HIC-1 in all three cell lines, and increased expression of 14-3-3σ in MiaPaCa and 
U251 cell lines.  Unmethylated RASSF1A was detectable within 24 hours of zeb 
treatment.  Treatment of all three cell lines with zeb for 24 hours prior to treatment 
with up to 8 gray (Gy) increased radiosensitivity.  The maximum increase in 
radiosensitivity was observed following zeb treatment for 48 hours prior to 
irradiation.6 
In vivo effects of the combination of zeb and radiation were investigated in 
male NCr nu/nu mice implanted with U251 xenografts.  To determine the 
demethylating activity of zeb in U251 xenografts, zeb was administered at 350 mg  
kg-1 by intraperitoneal injection for 5 days and tumor samples were evaluated by PCR 
for RASSF1A, HIC-1 and 14-3-3σ.  Expression of all three genes was maximized 
following three days of zeb treatment compared to controls, with no increase detected 
with additional days of treatment.  Mice were randomized to no treatment, zeb alone, 
radiation alone (4 Gy) or zeb and radiation, and then tumor growth was evaluated.  
The time for tumors to reach a size of 1,400 mm3 in mice treated with the 
combination of zeb and radiation was significantly increased compared to all other 
treatment groups.6 
Kim et al. investigated six DNMT inhibitors including 5-Aza-CR, 5-Aza-CDR, 
zeb, hydralazine, epigallocatechin gallate (EGCG) and psammaplin A on 
radiosensitivity in vitro in A549 (human lung cancer with a wild type p53) and 
U373MG (human glioblastoma with an inactive p53 mutant) cell lines.  A zeb 
concentration of 800 µM was used because this was the in vitro IC50 for these cell 





to 8 Gy resulted in significantly enhanced radiation cell killing in both cell lines.  
Western blot revealed depletion of DNMT1 and DNMT3a in both cell lines following 
treatment with 5-Aza-CDR, zeb and psammaplin A, but no change in DNMT3b.7 
γH2AX expression, which is associated with radiation induced double strand 
DNA breaks, is increased following irradiation with zeb pretreatment.6,7  In MiaPaCa, 
U251 and DU145 cell lines pretreated with zeb followed by irradiation, γH2AX 
expression was not increased one hour following irradiation, but was significantly 
greater at 24 hours when compared to controls treated with irradiation alone.6  
Similarly, γH2AX expression in A549 and U373MG cell lines was no different 1 hour 
after irradiation with 5-Aza-CDR, zeb and psammaplin A pretreatment, but increased 
significantly over time compared to irradiation alone.7  Increased γH2AX expression 
suggests persistent, unrepaired double strand breaks and that zeb enhanced 
radiosensitivity may be due to inhibition of DNA repair.6,7  
Meador et al. determined that the DNA-dependent protein kinase (DNA-PK) 
deficient human glioblastoma cell line MO59J was more sensitive to zeb treatment up 
to 300 µM compared to MO59K, a DNA-PK proficient human glioblastoma cell line.  
DNA-PK is a member of the phosphatidylinositol-3 kinase super family and normally 
functions to remove DNA damage such as double strand breaks or adducts.  DNA-PK 
deficient cells are inherently sensitive to radiation due to an inability to repair DNA 
damage.  Prolonged G2/M arrest is usually detected in DNA-PK deficient cells, but 
this arrest was not detected following zeb treatment in the MO59J cell line. Following 
treatment with zeb, the MO59J cell line demonstrated increased genomic instability 





micronuclei formation indicating chromosome breakage and mis-segregation.  
DNMT1 is normally involved in the repair of UV-laser induced double strand breaks, 
and its depletion by zeb may result in impaired DNA repair.  Defects in DNA repair 
and cell cycle checkpoint mechanisms resulted in enhanced zeb cytotoxicity as a 
single agent in the DNA-PK deficient MO59J cell line.12 
Demethylation and reactivation of specific genes and increased 
radiosensitivity has been demonstrated following zeb pretreatment in vitro and in 
vivo.6,7  Results of these studies suggest that the combination of radiation therapy and 
zeb pretreatment may be clinically useful.  Evidence suggests that radiosensitivity 
may be enhanced following zeb pretreatment due to inhibition of DNA repair, 
potentially due to depletion of DNMT1 or enhancement of inherently dysregulated 
cellular pathways within a tumor such as DNA-PK.6,7,12  Zeb’s increased uptake in 
tumor cells compared to normal cells10 would support its utility as a radiosensitizer, 
as it would be expected to accumulate in tumor tissue and not nearby normal tissues.  
While the use of high concentrations of zeb have been reported prior to irradiation, 
the minimum zeb concentration required to achieve enhanced radiosensitivity remains 
unknown.  Future efforts should be aimed not only at determining the optimal 
delivery schedule, but the minimum zeb dose required to achieve the desired 
radiosensitization. 
 
2.7 Zebularine inhibits tumor growth and reactivates silenced genes 
Zeb administered by intravenous or intraperitoneal injection, oral gavage or in 





mice13, transgenic mice14, mice harboring tumor xenografts15-17 and mice with 
radiation-induced tumors.18  Demethylating activity that correlates with tumor 
responses including stable disease, delayed or decreased tumor development and 
decreases in tumor volume compared to untreated controls have been reported.13-18 
The reported dose of zeb administered to mice has varied between studies.  
Neuriter et al. reported the use of a relatively high dose of 1,000 mg kg-1 by 
intraperitoneal injection in mice with pancreatic tumor xenografts.  Male NMRI mice 
with human Panc-89 cells implanted into the flank were allowed to develop seven 
millimeter tumors.  Mice were then treated daily for seven days with either zeb or 
saline by intraperitoneal injection.  Tumors in zeb treated mice remained stable in size 
over the seven day period, while there was a statistically significant increase in size of 
tumors in saline treated controls.  Untreated tumors increased in size by 33% over the 
same period of time.15  While shrinking tumors is often considered the goal of 
chemotherapy, arresting tumor growth may be sufficient to improve patient outcomes 
in many tumor types. 
Herranz et al. used a lower zeb dose in a long-term injectable treatment 
protocol in C57BL/6J mice treated with gamma irradiation to induce T-cell thymic 
lymphoma.  Mice were treated with 400 mg kg-1 by intraperitoneal injection for 78 
days or phosphate buffered saline.  Control mice treated with phosphate buffered 
saline died, as expected, of thymic lymphoma within six months of irradiation.  Mice 
treated with zeb had significantly improved survival compared to controls.  Of 30 
mice treated with zeb, 40% (n=12) were still alive 12 months after irradiation. 





in the thymus of mice treated with zeb that survived for 12 months when compared to 
thymic lymphomas that developed in controls.  Demethylation of hypermethylated 
promoters of p16Ink4a, MGMT, MLT-1, and E-cadherin was detected along with 
expression of the protein products.  No remarkable toxicity was detected and 
thorough necropsies were performed.18  This is one of the longest reported zeb 
treatment protocols in mice, and demonstrated that continuous zeb administration was 
feasible and safe in mice. 
Zeb was the first demethylating agent to demonstrate effective demethylation 
and antitumor effects following oral administration.  Cheng et al. treated mice with 
bladder cancer xenografts with up to 1,000 mg kg-1 zeb by oral gavage or 
intraperitoneal injection.  Male BALB/c nu/nu mice had EJ6 bladder cancer cells 
implanted into the flank, and were then treated with zeb for 18 days.  Minimal weight 
loss and no deaths were reported in treated mice.  Tumor growth was significantly 
inhibited following treatment with 1,000 mg kg-1 orally or by intraperitoneal injection.  
The p16 promoter, which is normally methylated in EJ6 cells, was significantly 
hypomethylated in tumors from mice treated with 500 or 1000 mg kg-1 orally or 
intraperitoneally compared to untreated controls.  The detection of tumor growth 
inhibition and demethylating effects in vivo following oral administration confirmed 
zeb’s stability and demonstrated its clinical potential.17 
Zeb also appeared to be effective following oral administration at even lower 
doses in mice.  Female BALB/c nu/nu mice had BGC823 gastric cancer cells 
implanted into the flank, and were then treated with up to 100 mg kg-1 by oral gavage 





significantly decreased tumor weight was detected at day 20 for doses of 10 mg kg-1, 
50 mg kg-1 or 100 mg kg-1 compared to controls.  Expression of p16 and BAX 
increased and expression of BCL-2 decreased as zeb concentration increased.16 
Alternatives to oral gavage including spiking drinking water with zeb have 
also been reported.  Treatment with zeb in drinking water was well tolerated in a 
majority of Min mice and resulted in tumor reduction in female mice.  These mice 
harbor a defect in the APC gene that leads to development of benign intestinal 
adenomas.  Most mice treated with 0.2 mg mL-1 zeb in drinking water from birth for 
120 days appeared to be normal and healthy, but 14% died between weeks five and 
seven of treatment.  Importantly, this mortality may be a result of an exaggerated 
sensitivity to zeb in Min mice as a dose of 1 mg mL-1 resulted in 100% death and a 
dose of 0.1 mL-1 resulted in 100% survival.  In female Min mice, average polyp 
number decreased from 58 to one.  In male Min mice, there was no change in the 
average polyp number.  There were no reported differences in toxicity based on sex.13  
This was the first report of a sex difference in mice treated with zebularine.  This 
difference may be explained by differential activity of aldehyde oxidase in male mice 
compared to females.19  The role of aldehyde oxidase in zeb metabolism is further 
discussed later in this chapter. 
While Min mice died following a dose of 1 mg mL-1 zeb in drinking water, 
transgenic female FVB/N-Tg(MMTV-PyMT)634Mul mice tolerated treatment with 5 
mg mL-1 zeb in drinking water.  These mice spontaneously develop mammary tumors 
by 60 days of age.  Zeb treatment began at 46 days of age and resulted in a 





untreated controls.  Mice were treated for 48 days and then sacrificed to determine 
total tumor burden, which was significantly decreased in treated mice compared to 
controls.  Treatment morbidity and mortality were not reported.14 
Overall, zeb is reportedly well tolerated over a wide range of doses and routes 
of administration in mice.  Significant tumor responses and changes in DNA 
methylation have been detected in vivo, providing strong evidence that zeb may be 
clinically useful. 
 
2.8 Zebularine pharmacokinetics in mice, rats and rhesus monkeys 
Initial investigation into zeb’s pharmacokinetics was performed in mice, rats 
and rhesus monkeys.  Animal subjects consisted of five to six week old male CD2F1 
mice, seven to eight week old male Fischer 344 rats and six to nine year old male and 
female rhesus monkeys (Macaca mulatta).  Mice received a zeb dose of either 100 
mg kg-1 intravenously or 1,000 mg kg-1 orally.  Rats received a zeb dose of either 50 
mg kg-1 intravenously, 250 mg kg-1 orally or 500 mg kg-1 orally.  One male and one 
female rhesus monkey each received a zeb dose of either 500 or 1,000 mg kg-1 
intravenously on day one and then the same dose orally 16 days later.  Serial blood 
samples were collected over the next 24 to 48 hours and processed to plasma.20 
 Peak zeb plasma concentrations following intravenous injection in mice were 
between 354 and 702-µg mL-1 (1,550 to 3,070 µM), half-life was 40 minutes with an 
AUC of 7,323 µg mL-1.  Peak zeb plasma concentrations following oral 





minutes.  Plasma zeb remained above the lower limit of quantification (0.03 µg mL-1) 
for 960 minutes.  AUC was 4,935 µg mL-1 and oral bioavailability was 6.7%.20 
Peak zeb plasma concentrations following intravenous injection in rats were 
between 165 and 238-µg mL-1 (723 to 1,040 µM), half-life was 363 minutes with an 
AUC of 12,526 µg mL-1.  Peak zeb plasma concentrations following oral 
administration of 250 mg kg-1 in rats were between 10 and 11 µg mL-1 (44 to 48 µM) 
at 120 minutes.  AUC was 1,969 µg mL-1 and oral bioavailability was 3.1%.  Peak zeb 
plasma concentrations following oral administration of 500 mg kg-1 in rats were 
between 31 and 32 µg mL-1 (135 to 140 µM) at 120 minutes.  The AUC was 7,612 µg 
mL-1 and oral bioavailability was 6.1%.20 
 Intravenous administration of 500 mg kg-1 resulted in a peak zeb plasma 
concentration of 1,094 µg mL-1 (4,794 µM) in a male rhesus monkey and 537 µg mL-1 
(2,350 µM) in a female rhesus monkey at five minutes.  Plasma zeb concentration 
decreased to below the level of quantification after 480 minutes in the male monkey 
and 240 minutes in the female monkey.  Estimated half-life was 70 and 76 minutes, 
AUC were 88,020 and 46,080 µg mL-1.  Oral administration of 500 mg kg-1 resulted 
in a peak zeb plasma concentration of 0.37 and 0.18 µg mL-1 (1.6 and 0.79 µM) at 60 
and 30 minutes.  AUC was 84 and 12 µg mL-1.  Oral bioavailibilities following an 
oral dose of 500 mg kg-1 were 0.1% and 0.026%.20   
 Intravenous administration of 1000 mg kg-1 resulted in a peak zeb plasma 
concentration of 1,656 µg mL-1 in a male rhesus monkey and 2,853 µg mL-1 in a 
female rhesus monkey at five minutes.  Plasma zeb concentration was above the level 





and 147 minutes, and AUC was 104,520 and 281,220 µg mL-1.  Oral administration 
of 1,000 mg kg-1 resulted in peak zeb plasma concentrations of 0.5 and 0.92 µg mL-1 
at 30 minutes and 8 hours.  AUC was 42 and 1,128 µg mL-1.  Oral bioavailabilities 
following an oral dose of 1,000 mg kg-1 were 0.04% and 0.4%.20 
 Based on the pharmacokinetic parameters determined in mice, rats and rhesus 
monkeys, frequent administration of zeb was recommended in order to achieve 
desired plasma levels.  The relatively low bioavailability, particularly in rhesus 
monkeys, was surprising and led to the suggestion that continuous intravenous 
administration or frequent oral dosing would be required.  The reason for the low 
bioavailability, particularly in rhesus monkeys, was unknown, but suggested causes 
included first pass metabolism by aldehyde oxidase or saturation of an absorption 
pathway in the intestines.20 
Interestingly, when male cynomolgus monkeys (Macaca fascicularis) were 
treated with continuous zeb infusions for five days out of seven designed to achieve 
plasma concentrations of 10 or 15 µM, toxicity was detected.  Toxicity included 
elevated white blood cell counts, reticulocyte counts, alanine aminotransferase (ALT), 
lactate dehydrogenase (LDH) and creatine kinase (CK).  Treatments designed to yield 
plasma concentrations of 25 to 50 µM or bolus intravenous injections of 500, 750 or 
1000 mg kg-1 proved lethal.  Rapid rises in zeb plasma concentrations prior to death 
were suggestive of impaired zeb clearance, possibly due to liver or kidney injury.  






2.9 Aldehyde oxidase and zebularine metabolism 
Zeb is ultimately metabolized to uridine, uracil and dihydrouracil, all of which 
are normally present in the body.  In a study of zeb metabolism in male CD2F1 mice, 
approximately 38% of zeb was oxidized to uridine by aldehyde oxidase (AO).22  AO 
activity was evaluated in hepatic cytosol from mice, rats, humans, a male cynomolgus 
monkey and a male Beagle dog.  Among the species in which activity was detectable, 
the activity was highest in male mice and lowest in female mice.  Activity was not 
detectable in hepatic cytosol from a male Beagle dog.  A 50-fold difference was 
detected between male and female mice, but a similar magnitude of difference was 
not detected between sexes in rats or humans.19  there is often greater AO homology 
between mice and humans than monkeys and humans.4   
Supraphysiologic concentrations of uridine have been reported to cause 
hyperthermia and hypothermia in mice.  In humans, prolonged infusions of uridine 
have been reported to cause hyperthermia and shivering has been reported during 
shorter high dose infusions.  The shivering reported in humans does not appear to be 
due to changes in body temperature, and may be due to interference in the 
metabolism of neurotransmitters like dopamine and neuropeptide.  Based on body 
surface area, a dose of 100 mg kg-1 in the mouse would be equivalent to a dose of 8 
mg kg-1 in humans.  This dose would result in a uridine exposure of 3 mg kg-1, which 
is much lower than pharmacologic doses ranging from 150 to 1,000 mg kg-1 d-1 
currently used to treat human diseases.  The production of uridine can also decrease 





assessed, zeb did decrease the activity of 5-fluorouracil against human oral squamous 
cell carcinoma cell lines in vitro when the two drugs were combined.23 
While exposure to uridine is unlikely to pose a significant risk, the production 
of hydrogen peroxide when AO converts zeb to uridine may pose a risk.  In all 
species that express AO, its activity is highest in the liver.22  Elevations in ALT and 
LDH were detected in male cynomolgus monkeys treated with zeb to achieve plasma 
concentrations of 10 to 15 µM.  Zeb was lethal in cynomolgus monkeys treated to 
target plasma concentrations of 25 to 50 µM or with bolus intravenous injections 
greater than 500 mg kg-1.  In these monkeys, zeb plasma concentrations rapidly 
increased prior to death, suggesting that liver or renal injury resulted may have 
decreased zebularine clearance.  Bolus intravenous dosing of ≤ 250 mg kg-1 did not 
result in any deaths, but elevations in hepatic and renal parameters were detected.21  
Production of large amounts of hydrogen peroxide resulting in massive hepatocellular 
injury could account for the apparent liver injury observed in monkeys. 
If differences in AO activity were responsible for differences in toxicity, then 
a difference in toxicity would be expected in mice since there is a 50-fold difference 
in AO activity between the sexes.  While no difference in toxicity has been detected 
between male and female mice, differences were detected in tumor prevention in Min 
mice.  Following treatment with zeb, the number of tumors that develop in female 
mice is significantly decreased, but not in male mice.13  The implication of the lack of 
AO activity in the dog is unclear, as is the true cause of the hepatic toxicity in 
monkeys.  It is unknown whether or not similar toxicity would be observed in dogs or 





2.10 Invasive transitional cell carcinoma in man and the dog 
Around the world, human bladder cancer accounts for 3.3% of newly 
diagnosed cases and 2.1% of all cancer deaths.24  Bladder cancer is the 5th most 
common cancer diagnosed in the United States.  Treatment is often very involved and 
costly due to frequent tumor recurrence.  While most humans develop non-invasive, 
superficial bladder tumors that can be successfully treated locally by instillation of 
therapeutic agents directly into the bladder or transurethral tumor resection, some will 
go on to develop muscle InvTCC.  Others will have invasive cancer already present at 
diagnosis.25  In 2008, an estimated 386,300 new cases of bladder cancer were 
diagnosed, and 150,200 people died due to bladder cancer around the world.26  More 
than 14,000 people in the United States died due to InvTCC in 2011.27 
In contrast to humans in which lower grade superficial bladder tumors 
predominate, InvTCC is the most common cancer affecting the urinary tract in the 
dog.28  While the true prevalence is unknown, InvTCC is estimated to account for up 
to 2% of all canine cancers.27,28  Risk factors for the development of InvTCC in the 
dog include use of older generation topical insecticides and dips, obesity, female sex 
and breed.28  Scottish Terriers are at a 20-fold increased risk.28  Exposure of Scottish 
Terriers to phenoxy herbicides like 2,4-D further increases the risk of InvTCC.29  
Other breeds including Beagles, Shetland Sheepdogs, Wire Hair Fox Terriers and 
West Highland White Terriers are also at an increased risk.  Half or more of dogs 
diagnosed with InvTCC will develop distant metastasis by the time of death.  The 
most common sites of metastasis are the lungs and regional lymph nodes.  Death 





Dogs with naturally occurring InvTCC offer a highly relevant model of 
aggressive bladder cancer in humans due to similar clinical, cellular and biological 
features, and responses to chemotherapy.27,30  Most InvTCC-related deaths in dogs 
and humans are due to non-resectable chemotherapy-resistant cancer. Developing 
novel strategies to improve treatment efficacy is essential for both dogs and humans. 
Overexpression of genes including bFGF, COX1 (PTGS1) and COX2 (PTGS2) and 
mutations in TP53 are present in both human and canine InvTCC.30   
While the methylation patterns in canine InvTCC have not been investigated27, 
methylation patterns in human superficial bladder cancer and InvTCC have been 
investigated.  The development of bladder cancer in humans is known to involve 
multiple oncogenes and tumor suppressor genes, including FGFR3, HRAS, CDH1, 
CDKN2A (p16INK4a and p14ARF), HOXB2, RASSF1A, RB1, SFRP2 and 
WAF1.25,30,31  DNA hypermethylation is known to cause transcriptional silencing of 
many of these genes in human bladder cancer.30  Hypermethylation of specific genes 
is frequently reported in human bladder cancer, but with inconsistent results.32  For 
example, Zhu et al. reported hypermethylation of MLH1, HOXA9, SLT2 and HIC-1 in 
a variety or bladder carcinomas compared to adjacent normal tissues, but were unable 
to demonstrated hypermethylation of RASSF1A, MGMT and p16, which had 
previously been reported.  Other changes important in urothelial carcinogenesis 
include deletions of chromosome 9 and defects in p53.31  Global hypomethylation is 







Specific methylation patterns are not consistent across all human bladder 
tumors, but methylation status is associated with advanced tumors and tumor 
progression.  Yates et al. investigated promoter methylation within 17 genes from 96 
malignant urothelial cancers and 30 normal samples.  Statistically significant higher 
rates of methylation were detected in eight of 17 genes (WIF-1, TNFRSF25, EDNRB, 
APC, MGMT, BCL2, hTERT, IGFBP3) for malignant tumors versus normal tissue.  
No statistically significant differences were detected for RASSF1A, DAPK, RARβ, 
CYCLIND2, TIMP3 and HIC-1 or CDH1, CDH4 and P16 after applying Bonferonni’s 
correction.  Methylation at these 17 loci was significantly increased in poorly 
differentiated urothelial cancers compared to well-differentiated tumors, and invasive 
tumors compared to superficial tumors.  Tumors that had methylated TNFRSF25, 
EDNRB, RASSF1A, APC and CDH1 were significantly more likely to progress to a 
more aggressive stage of disease and result in patient death.  No tumors that lacked 
methylation or had methylation of one gene progressed.  Patients could be stratified 
based on their risk of developing disease progression using subsets of these genes, 
suggesting that assessment of methylation status may be useful in determining what 
patients should undergo more vigilant monitoring.33  The ability to predict which 
patients are unlikely to develop tumor recurrence could result in significant cost 
savings, and direct resources toward patients more likely to develop tumor recurrence.  
 
2.11 Investigation of DNMT1 in canine InvTCC cell lines 
Expression of DNMT1 has been demonstrated in human InvTCC and other 





InvTCC.27  Microarray gene expression profiling demonstrated a 2.28-fold increase in 
DNMT1 expression in biopsy samples from four dogs with InvTCC compared to 
samples of bladder mucosa from four normal dogs.  Positive DNMT1 
immunoreactivity (>10% of cells with positive nuclear staining) was detected in 45% 
(n=10) of canine biopsy samples and no immunoreactivity was detected in bladder 
samples from normal dogs (n=6).27  DNMT1 would be expected in a greater 
proportion in rapidly proliferating tissues as it is highly expressed during S-phase. 
Increased DNMT1 expression in canine InvTCC appeared to be a rational 
target for treatment with DNMT1 inhibitors, and further investigation was performed 
in three canine InvTCC cell lines (K9TCC, K9TCC-PU-Sh, K9TCC-PU-Nk).  Cell 
lines were treated with the DNMT inhibitor 5-Aza-CR, the histone deactylase 
inhibitor trichostatin A or the combination.  Treatment with trichostatin A alone 
resulted in morphologic changes in all three cells lines.  Treatment with either 5-Aza-
CR or trichostatin A resulted in decreased cell counts, but the combination resulted in 
a larger decrease.  Decreased DNMT1 protein was detected by Western blot in two of 
three cell lines (K9TCC and K9TCC-PU-Sh) following treatment with 5-Aza-CR.  
Decreased DNMT1 protein was detected in all cell lines following treatment with 
trichostatin A.27 
Following treatment with 5-Aza-CR, p16 was slightly increased in all three 
cell lines, and p21 was decreased in one cell line (K9TCC-PU-Sh).  Following 
treatment with trichostatin A or combination 5-Aza-CR and trichostatin A, there was 





survivin & PARP in all three cell lines.  Expression of p16 was slightly greater 
following combination treatment in K9TCC than with trichostatin A alone.27 
The p16 gene is often silenced by hypermethylation in human cancers, and 
therefore, the increase in p16 protein following treatment of canine InvTCC cell lines 
with 5-Aza-CR, TSA or the combination is of considerable interest.  These results 
suggest that while the DNMT inhibitor 5-Aza-CR has some activity alone, the 
addition of an HDAC inhibitor like TSA may yield better results.  As the safety, 
toxicity and efficacy of most DNMT inhibitors and HDAC inhibitors have not been 
assessed in dogs with cancer, further investigation of these agents alone and then in 
combination is indicated.27 
 
2.12 Investigation of 5-Aza-CR in dogs with InvTCC 
A phase I study of subcutaneous 5-Aza-CR was performed in dogs with 
naturally occurring InvTCC to determine if further studies should be performed in 
humans with InvTCC.  This dog study was performed to assess toxicity, antitumor 
activity and a dose range for subsequent work.  5-Aza-CR was administered 
subcutaneously once daily for five days once every 14 days or 28 days.  Dogs were 
initially treated with a dose of 0.2 mg kg-1 per day, which is equivalent to 10% of the 
FDA approved dose of 5-Aza-CR for the treatment of myelodysplastic syndrome in 
humans.  Dose-limiting toxicity (DLT) was defined as any grade 3 or 4 Veterinary 
Cooperative Oncology Group common terminology criteria for adverse events v1.1 
(VCOG-CTCAE v1.1) adverse event, and the maximum tolerated dose (MTD) was 





experienced a DLT.  A total of 19 dogs were enrolled.  One dog was excluded from 
evaluation of tumor response due to concurrent non-steroidal anti-inflammatory drug 
(NSAID) administration.  Eleven dogs were treated for five consecutive days once 
every 28 days, and eight dogs were treated for five consecutive days once every 14 
days.  Of the dogs enrolled, 73% had failed prior therapies.30 
The most common adverse events following treatment with 5-Aza-CR were 
myelosuppression, including grade 3 or 4 neutropenia, and gastrointestinal upset, 
including grade 3 or 4 nausea and anorexia.  The MTD was determined to be 0.1 and 
0.2 mg kg-1 per day when 5-Aza-CR was given for five consecutive days once every 
14 days or 28 days, respectively.  Decreased tumor volume was detected in 55.6% 
(n=10) of dogs, and 22.2% (n=4) achieved partial remission (PR; ≥50% or greater 
decrease in tumor volume).  While no complete remissions (CR; complete resolution 
of all lesions) were detected, the disease control rate, defined as the combination of 
CR, PR and stable disease (SD; <50% increase or decrease in tumor volume for at 
least 8 weeks), was 72.2% (n=9).30 
Samples of peripheral blood mononuclear cells (PBMCs) and bladder tumor 
tissue were collected for gene-specific (CDKN2A/p14ARF) and global methylation 
assays.  No significant differences in global DNA methylation were detected in paired 
pre- and post-treatment PBMCs from 12 dogs.  Non-statistically significant decreases 
in global DNA methylation ranging from 0.74% to 8.43% were detected in six dogs.  
No significant differences in global DNA methylation were detected in paired pre- 
and post-treatment tumor biopsy samples from 10 dogs.  Non-statistically significant 





seven dogs.  A 6.8% decrease in CDKN2A (p14ARF) methylation was detected in one 
dog that achieved PR and had paired tumor samples for analysis.30 
 Treatment with 5-Aza-CR was generally well tolerated in dogs with InvTCC, 
with reversible myelosuppression and gastrointestinal toxicity as the most clinically 
relevant toxicity.  While no complete remissions were detected, the overall response 
rate of 72.2% and observation of a decrease in tumor volume in 56% of dogs was 
promising, particularly when taking into account that 73% of treated dogs had failed 
prior therapy.  The lack of statistically significant DNA hypomethylation and 
myelosuppression observed in this study may indicate that the tumor responses 
observed were due to cytotoxic effects as opposed to demethylating activity.  
Cytotoxicity is known to occur at some doses of 5-Aza-CR, and these doses have not 
been well defined in the dog.  Similarly, tumor responses without detectable changes 
in DNA methylation have been observed in human cancers treated with drugs thought 
to work through DNA demethylation.  The optimal timing of post-treatment sample 
collection is unknown, and the lack of significant changes could reflect that samples 
were not collected at the optimal time interval after initiating demethylating therapy.30  
Another possible explanation for lack of detection of gene-specific hypomethylation 
is inappropriate target selection.  CDKN2A (p14ARF) is frequently lost through 
deletions in human bladder cancer 32, thus it may not even be present to undergo 
demethylation.  Similarly, genes other than CDKN2A (p14ARF) may have undergone 






Investigation of demethylating agents is just beginning in pet dogs.  Treatment 
of dogs with InvTCC 5-Aza-CR was generally well tolerated and had a promising 
disease control rate of 72.2%.30  Canine InvTCC cell lines appear to have increased 
activity of DNMT1 that can be impaired by treatment with 5-Aza-CR, TSA or the 
combination.27  These studies provide a basis for the further exploration of 
demethylating therapy in pet dogs with InvTCC.  While 5-Aza-CR has shown 
promise, treatment involved frequent subcutaneous injections.30 Zeb’s stability offers 
a significant advantage over 5-Aza-CR2,3,4,17, particularly in the treatment of pet dogs, 
because it can be easily administered orally on a continuous schedule.  Despite its 
apparent low bioavailability in the initial pharmacokinetic study20, zeb was the first 
agent to demonstrate in vivo demethylating activity following oral administration.17  
Zeb was well tolerated in rodents, but marked hepatic toxicity and death were 
reported following high dose treatment in male cynomolgus monkeys.21  The cause of 
toxicity in cynomolgus monkeys is unknown, but the use of such high doses of zeb in 
the future would be unlikely.   
To the author’s knowledge, prior to the work described in the following 
chapters, no in vivo evaluation of zeb has been performed in the dog.  The purpose of 
the work described in the following chapters was to evaluate the pharmacokinetics 
and toxicity of zeb in laboratory dogs and tumor bearing dogs, and provide an initial 
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The purpose of this study was to determine the plasma pharmacokinetics and toxicity of 





zeb concentrations were determined by HPLC-MS/MS following an oral zeb dose of 8 or 
4 mg kg-1.  Plasma zeb clearance was constant.  Mean Cmax was 23 ± 4.8 and 8.6 ± 1.4 
µM following 8 and 4 mg kg-1, respectively.  Mean half-life was 5.7 ± 0.84 and 7.1 ± 2.1 
following 8 and 4 mg kg-1, respectively.  A single 8 mg kg-1 dose was well tolerated.  
Daily 4 mg kg-1 treatment in 3 laboratory dogs resulted in grade 4 neutropenia (n=3), 
grade 1 anorexia (n=2) and grade 1 or 2 dermatologic changes (n=2).  All adverse events 
resolved with supportive care.  A 4 mg kg-1 dose every 21 days was well tolerated.  A 
follow up dose escalation study is in progress with a lower starting dose.   
 
3.3 Introduction 
DNA methylation is an important epigenetic modification that often occurs on 
cytosines within cytosine guanine dinucleotides (CpGs).1,2  CpGs are concentrated within 
gene promoter regions in half of all human genes.1  Hypermethylation of DNA within the 
promoter region of a tumor suppressor gene can result in functional silencing of the gene 
and an increased risk of cancer development or progression.  DNA methylation patterns 
are maintained by DNA methyltransferases (DNMTs) during DNA replication.  Unlike 
genetic mutations, epigenetic changes are potentially reversible.1,2 
Zeb (1-β-D-Ribofuranosyl-2(1H)-pyrimidinone) is a cytidine analog that was 
originally identified as a bacteriostatic drug, then determined to be a cytidine deaminase 
(CDA) inhibitor and more recently determined to be a DNMT inhibitor.2,3  Zeb is 
incorporated into DNA in place of cytidine and forms a complex with DNMTs, thus 





similar to that of 5-azacytidine (Vidaza®, Celgene Corp., Summit, NJ, USA; 5-Aza-CR) 
and decitabine (Dacogen®, SuperGen, Inc., Dublin, CA, USA; 5-Aza-CDR), which are 
currently FDA approved for the treatment of human cancers.3  Unlike 5-Aza-CR and 5-
Aza-CDR, zeb is stable at a broad pH range and is not subject to rapid inactivation by 
CDA.2,3  In addition, zeb acts as a radiosensitizer in vitro, which may be due to inhibition 
of DNA repair.4,5   
Dogs with naturally occurring cancer offer an excellent opportunity to evaluate 
and optimize new cancer treatment strategies including those involving demethylating 
agents.6,7  The injectable DNMT inhibitor 5-Aza-CR has been investigated in dogs with 
invasive transitional cell carcinoma (InvTCC) of the urinary bladder with promising 
results.  Subcutaneous injections were administered daily for five consecutive days at two 
or four week intervals in 18 dogs, resulting in 22% partial remission and 50% stable 
disease for more than eight weeks.7  Daily oral administration is likely to be the most 
convenient dosing strategy and potentially the most efficacious since demethylating 
agents requires actively dividing cells, making zeb an attractive drug to investigate in 
subsequent studies.8,9  
Previous pharmacokinetic and toxicity assessment of zeb has been performed in 
mice, rats and rhesus monkeys.10  Zeb administered by intravenous or intraperitoneal 
injection, oral gavage or in drinking water was well tolerated in vivo in genetically tumor-
prone mice, transgenic mice and mice harboring tumor xenografts.  Demethylating 
activity correlated with tumor responses including stable disease, delayed or decreased 
tumor development and decreases in tumor volume compared to untreated control 





clinicopathologic evidence of liver and kidney injury were detected.  Further dose 
elevations were lethal.17  
In vivo evaluation of zeb has not been performed in the dog.  Previous study in the 
dog is limited to an in vitro zeb plasma protein binding assay performed on samples from 
Beagle dogs.10  The purpose of this study was to evaluate the pharmacokinetics and 
toxicity associated with oral zeb administration in laboratory dogs and dogs with 
naturally occurring cancer.  
 
3.4 Materials and Methods 
Study subjects 
All work was approved by the Purdue Animal Care and Use Committee.  
Laboratory dogs were obtained from Marshall Farms (North Rose, New York, USA) and 
then housed and evaluated in  the Clinical Discovery Laboratory, College of Veterinary 
Medicine, Purdue University.  Privately owned, tumor bearing dogs undergoing treatment 
at the Purdue University Veterinary Teaching Hospital (PUVTH) were enrolled following 
informed written pet owner consent.  Entry criteria included a definitive diagnosis of 
cancer via histopathology, measurable cancer and  expected survival time of at least 6 
weeks.  Dogs were allowed to enroll if they had failed other cancer therapy or if other 
therapy had been declined for any reason.  Dogs were allowed to continue non-steroidal 
anti-inflammatory drugs (NSAIDs) if needed for pain control, and if cancer progression 
had been documented during NSAID treatment prior to zeb administration.  Tumor 







Pharmaceutical grade zeb was provided through the National Cancer Institute’s 
Experimental Therapeutics (NExT) Program as a bulk powder.  Zeb was compounded 
into gelatin capsules in sizes ranging from 5 to 20 mg by Diamondback Drugs, LLC 
(Scottsdale, AZ, USA). 
 
Zebularine plasma pharmacokinetics 
Plasma pharmacokinetic analysis was performed in samples from dogs following 
a single oral dose of 8 mg kg-1 or 4 mg kg-1 with food.  Laboratory dogs (n=3) received 8 
mg kg-1, and pet dogs received 4 mg kg-1.  Doses were rounded to the nearest 5 mg due to 
capsule size.  Serial venous blood samples were collected prior to the first treatment and 
at 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 hours following zeb administration to obtain the 
plasma concentration versus time profile.  Following collection into ethylenediamine-
tetraacetic acid (EDTA) blood collection tubes, blood samples were immediately 
centrifuged (1,800 g, 15 min, 4°C), and plasma was collected.  Samples were stored at 
-80 °C until analysis. 
Analyses were performed by the Clinical Pharmacology Analytical Core Facility 
at Indiana University School of Medicine, Indianapolis, IN, USA.  Zeb was quantified in 
plasma using 5-Aza-CR as the internal standard, liquid-liquid extraction, and HPLC-
MS/MS (Thermo Accela pump and Thermo TSQ Quantum Ultra MS/MS; Thermo 
Fisher).  Zeb and 5-Aza-CR were separated by gradient mobile phase (acetonitrile:5mM 
ammonium formate) and HPLC using a C8 column (Zorbax, 5 µm 250 X 4.6 mm).  The 





respectively.  The lower limit of quantification (LOQ) is 1 ng mL-1 using 200 µL of 
plasma.     
Pharmacokinetic parameters for zeb including area under the curve (AUC), area 
under the moment curve (AUMC) and the elimination rate constant, kel, were estimated 
using noncompartmental methods with add-ins on Excel®.  The half-life (t1/2) was 
estimated by 0.693 kel-1.  Zeb AUC was estimated from time zero to infinity.  The AUC 
from the last concentration, Clast, to infinity was estimated by Clast kel-1.  The systemic 
clearance (Cl F-1, where F is the bioavailability) was calculated from the dose and   
AUC0-∞ and the volume of distribution at steady state (Vdss F-1) was calculated from the 
Cl and the mean residence time (MRT; MRT =(Dose/AUC)x(AUMC/AUC).  The 




Zeb toxicity was assessed following daily oral dose of 4 mg kg-1 in laboratory 
dogs and an oral zeb dose of 4 mg kg-1 once every 21 days in tumor bearing dogs.  
Toxicity was assessed by physical examination, serial complete blood counts and serial 
serum biochemistry panels.  Serial complete blood counts and serum biochemistry panels 
were initially planned weekly and then performed as needed based on observed toxicity 
at the discretion of the attending clinician.  Toxicity was graded using the Veterinary 









Three laboratory dogs of approximately one year of age (one male intact Beagle, 
one female intact Beagle, and one female intact mixed breed dog) were enrolled.  The 
dogs weighed 11.4, 7.7 and 16.9 kgs respectively.  Initial pharmacokinetics assessment 
was performed following a single  oral dose of approximately 8 mg kg-1 (range 7.8 to 8.0 
mg kg-1), and toxicity assessment was performed following daily dosing of approximately 
4 mg kg-1 (range 3.8 to 3.9 mg kg-1).   
Three tumor bearing dogs (one 8.7 year old male neutered Beagle, one 9.6 year 
old male neutered mixed breed dog, and one 11.3 year old female spayed Labrador 
retriever) were enrolled.  The dogs weighed, 16.9, 27.9 and 30.6 kgs, respectively.  Two 
tumor bearing dogs had a histopathological diagnosis of InvTCC, and one had a diagnosis 
of a recurrent gastrointestinal stromal tumor (GIST).  One dog with InvTCC had been 
previously treated with an NSAID (carprofen) for pain and continued to receive an 
NSAID (piroxicam) at the time of enrollment.  One dog with InvTCC had previously 
failed one injectable chemotherapy drug (vinblastine) and one NSAID (firocoxib).  The 
dog with GIST had undergone surgery to remove the tumor, and the tumor recurred seven 
months later at the time zeb was initiated.  Pharmacokinetics assessment in these dogs 
was performed following the initial oral dose of approximately 4 mg kg-1 (range 3.8 to 









Pharmacokinetics results are summarized in Table 3.1 and zeb concentration 
versus time curves are shown in Figure 3.1.  Following an oral dose of 8 mg kg-1, the 
mean tmax was 1.2 ± 0.62 hours, mean t1/2 was 5.7 ± 0.84 hours, mean Cmax was 5280 ± 
0.84 ng ml-1, and mean AUC0-∞ was 35,358 ± 6132.6 ng ml-1.  Following an oral dose of 
4 mg kg-1, the mean tmax was 2.3 ± 1.2 hours, mean t1/2 was 7.1 ± 2.1 hours, mean Cmax 
was 1962 ± 320.3 ng ml-1, and mean AUC0-∞ was 17,206 ± 3221.4 ng ml-1. 
 
Zebularine toxicity – laboratory dogs treated daily with 4 mg kg-1 zebularine 
All three laboratory dogs treated with a daily oral zeb dose of 4 mg kg-1 
developed grade 2 (n=1) or grade 3 (n=2) neutropenia that progressed to grade 4 
neutropenia.  Zeb was discontinued when grade 2 or greater neutropenia was detected on 
day 14 (n=1), day 23 (n=1) and day 24 (n=1).  Neutropenia progressed to grade 4 
neutropenia by day 21 (n=1), day 29 (n=1) and day 30 (n=1).  Grade 1 thrombocytopenia 
was detected in one dog.  Grade 1 anorexia was detected immediately prior to grade 4 
neutropenia in two dogs.  No abnormalities were detected in serial serum biochemistry 
panels.  After marked neutropenia developed, supportive care was initiated including 
antibiotics (n=3), antiemetics (n=2) and intravenous crystalloid fluids (n=2).  All three 
dogs recovered, and neutrophil counts returned to normal within 16, 17 or 19 days, 
respectively.  No abnormalities were detected in serial serum biochemistry panels. 
Intermittent dermatologic changes were detected in two laboratory dogs including 





(n=1).  Dermatologic changes resolved without specific treatment after zeb was 
discontinued. 
The laboratory dogs underwent orchiectomy (n=1) or laparoscopic 
ovariohysterectomy (n=2), and had laparoscopic liver and kidney biopsies (n=3) 
performed prior to placement in permanent private homes.  Specific pathology was not 
detected in any of the samples that were collected.  Liver biopsies revealed non-specific, 
mild to moderate, reversible, hepatocellular degeneration in one dog and mild hydropic 
change in one dog.  Renal pathology was not observed.  
 
Zebularine toxicity – tumor bearing dogs treated once every 21 days with 4 mg kg-1 
zebularine 
Three tumor bearing dogs received six, four, and one dose(s) of zeb, respectively.  
Grade 1 thrombocytopenia was detected one week after the first zeb treatment in one dog.  
No dose adjustment was made, and thrombocytopenia did not recur.  No other 




The purpose of this study was to determine the plasma pharmacokinetics and 
assess toxicity of the novel demethylating agent, zeb, in laboratory and tumor bearing 
dogs.  The work builds upon that previously reported in mice, rats, and monkeys, and  
provides pivotal information required for subsequent investigation of zeb’s potential as a 





concentrations in dogs can be taken into account when interpreting in vitro and in vivo 
mechanisms studies. The constant plasma clearance and half-life of approximately four to 
nine hours, can be used in designing subsequent treatment studies in dogs.  Epigenetic 
based treatment strategies can be applied across several cancer types, but work in 
naturally occurring canine InvTCC is particularly intriguing as it serves as a relevant 
model of the cancer in humans.  Studies in dogs are expected to lead to the development 
of new treatment strategies that can be applied in both species.6 
The dog study contributed to the understanding of the potential toxicity of zeb.  
Following daily treatment with 4 mg kg-1 zeb, grade 4 neutropenia developed in all three 
laboratory dogs.  Although the myelosuppression resolved after zeb was discontinued, 
and all dogs recovered with supportive care, clearly lower zeb doses are indicated for 
follow-up studies.  The myelosuppression in dogs was not completely unexpected as this 
has occurred with other demethylating agents in dogs and humans, especially when the 
drugs are given at higher, cytotoxic doses.7,19  The degree of hematologic toxicity at the 4 
mg kg-1 dose in dogs, however, was not expected when considering the available 
published in vivo study results of zeb in other species.  Zeb was reported to be well 
tolerated in mice with no significant weight loss or mortality when administered for 
weeks to months.11-15  Although clinicopathologic assessments were not reported in the 
mouse studies, it would be expected that should severe myelosuppression have occurred, 
that infection and sepsis would have been noted in the mice. It is also possible that higher 
doses of zeb in mice could result in myelosuppression.  In male cynomolgus monkeys 
treated with five out of seven day intravenous infusions of zeb at <250 mg kg-1 per day 





it is not known if the blood counts were performed when the neutropenia would have 
occurred if it were going to occur at that dosage.  Regardless of whether the findings in 
dogs were expected or not, the documentation of the reversible, yet severe, 
myelosuppression in dogs is being used in the planning of additional studies of zeb in 
dogs.  A dose of 4 mg kg-1 every 21 days resulted in no appreciable toxicity in tumor 
bearing dogs.  A follow-up dog study is in progress in which the dose intensity of the 
starting dose cohort (daily 0.2 mg kg-1 zeb) is equivalent to the dose intensity of 4 mg kg-
1 once every 21 days.  This daily dose has been well tolerated to date in dogs. 
The dog study results were encouraging in that major internal organ toxicity was 
not observed in dogs at any of the doses given.  There has been concern for liver and 
kidney toxicity of zeb in other species.  In male cynomolgus monkeys treated with five 
out of seven day intravenous infusions at 250 mg kg-1 per day of zeb for two consecutive 
weeks, clinicopathologic changes included elevated alanine aminotransferase (ALT), 
lactate dehydrogenase (LDH) and creatine kinase (CK).  Higher zeb doses of 500, 750 or 
1,000 mg kg-1 given by continuous infusion or bolus resulted in lethal toxicity.17  Zeb 
plasma concentrations rapidly increased prior to death in the cynomolgus monkeys 
treated with very high dose zeb, raising the possibility that liver or renal injury could 
have resulted in decreased zeb clearance.17  While LDH and CK were not assessed in the 
current dog study, serum biochemistry panels did not reveal any evidence of liver or 
kidney injury following zeb treatment.  Evaluation of post-treatment liver and kidney 
biopsies did not reveal any specific pathologic changes. 
Differences in aldehyde oxidase (AO) activity or other not-yet-characterized 





metabolism, efficacy and toxicity across species and individuals.3,20,21  Among hepatic 
cytosol samples from mice, rats, humans and a male cynomolgus monkey, AO activity 
was highest in male mice and lowest in female mice.  AO activity was not detected in 
hepatic cytosol from a male Beagle dog.  A 50-fold difference was detected between 
male and female mice, but a similar magnitude of difference was not detected between 
sexes in rats or humans.22  There is often greater aldehyde oxidase homology between 
mice and humans than monkeys and humans.3  The effect of differential AO activity may 
account for differences in the effects of zeb on tumor development between female Min 
mice and male Min mice.  These mice harbor a defect in the adenomatous polyposis coli 
(APC) gene that leads to development of benign intestinal adenomas.  The number of 
tumors that developed in female, but not male, Min mice significantly decreased 
following treatment with zeb.  In Min mice, there were no reported sex differences in zeb 
toxicity.16  The lack of AO activity in the dog could result in improved bioavailability due 
to a decrease in first pass metabolism.  
While tumor response was not a primary end point of this study, and a very small 
tumor bearing cohort of dogs was evaluated, it was noted that the two dogs with InvTCC 
treated with zeb had stable disease (<50% change in tumor size and no new lesions) when 
treated with zeb once every 21 days for 12 to 18 weeks.  In dogs that have failed therapy 
with progressive disease, InvTCC often progresses rapidly, and lack of progression over 
3-4 months suggests beneficial drug activity.  In addition, when considering that the 
optimal dosing strategy for demethylating agents is likely daily administration7,9, the 
dosing strategy employed in tumor bearing dogs was unlikely to reflect the optimum 





effects of zeb could occur at doses considerably lower than those which were toxic in 
dogs.3  With a half-life in the dog ranging from approximately four to nine hours, near 
continuous exposure to zeb would be expected even with dosing once every 24 hours.  
Furthermore, the production of stable zeb metabolites may act as a depot for the drug, 
allowing for drug accumulation and recycling.23 
In summary, this study provided important information concerning the 
pharmacokinetics and toxicity of zeb in dogs.  A daily dose of zeb of 4 mg kg-1 resulted 
in unacceptable, but reversible, hematologic toxicity in laboratory dogs while a dose of 4 
mg kg-1 every 21 days resulted in no appreciable toxicity in tumor bearing dogs.  A daily 
dose of zeb (0.2 mg kg-1), which is equivalent to the dose intensity of 4 mg kg-1 once 
every 21 days, has been well tolerated in dogs to date.  Continued  investigation of zeb is 
warranted in tumor bearing dogs to determine the optimal dosing strategy, activity as 
both a single agent and in combination with other drugs and characterization of 
demethylating activity in vivo.   
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Table 3.1. Pharmacokinetic parameters from laboratory dogs treated with a 
single oral zebularine dose of 8 mg kg-1 (n=3) and tumor bearing dogs treated 
with a single oral zebularine dose of 4 mg kg-1. 
 

















Laboratory dogs – 8 mg kg-1 
1 16.9 135 4695 -- 2.0 43584 6.8 3.1 29.2 
2 7.7 60 6824 23 ± 4.8 0.5 33626 5.4 1.8 12.5 
3 11.4 90 4322 -- 1.0 28865 4.8 3.2 21.3 
Tumor bearing dogs – 4 mg kg-1 
1 16.9 65 1850 -- 2.0 12665 8.3 5.1 52.7 
2 27.9 110 2399 8.6 ± 1.4 1.0 19167 4.1 5.7 38.6 
3 30.6 120 1639 -- 4.0 19788 8.9 6.1 84.1 
Cmax:  maximum concentration 
tmax:  time of maximum concentration 
AUC0-inf:  area under the plasma concentration-time curve from 0-infinity 
t1/2:  half-life 
Cl/F:  clearance/availability; if dosage is IV, then F=1 











Figure 3.1. Zeb clearance in three laboratory dogs following a single oral dose of 
8 mg kg-1 (A) and three tumor bearing laboratory dogs following a single oral 
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A phase I clinical trial of zebularine (zeb) was performed in dogs with naturally occurring 
invasive transitional cell carcinoma (InvTCC).  A total of 26 dogs were enrolled in six 





included neutropenia following a daily zeb dose of 0.6 mg kg-1.  Based on results to date, 
the maximum tolerated dose (MTD) is likely to be 0.5 mg kg-1 per day.  Of the 26 dogs 
treated, 73% had failed treatments including NSAIDs, oral and injectable chemotherapy.  
Median progression free survival was 86 days (95% CI, 47.5-124.5).  Of 19 dogs 
evaluated for tumor response, 14 had stable disease for at least eight weeks, and five had 
progressive disease.  Zeb was well tolerated up to 0.5 mg kg-1 per day and further 
investigation of zeb alone or in combination in the dog should be targeted at this dose. 
 
4.3 Introduction 
Zeb is an oral demethylating agent with the potential to reactive silenced genes in 
cancer.1-5  Our group performed an initial investigation of the pharmacokinetics and 
toxicity of zeb in laboratory and tumor bearing dogs.  A zeb dose of 8 mg kg-1 per day in 
laboratory dogs resulted in remarkable but reversible neutropenia.  A zeb dose of 4 mg 
kg-1 once every 21 days was well tolerated in tumor bearing dogs (see Chapter 3).  A 
daily dosing schedule has been proposed as the optimum dosing strategy for 
demethylating agents.6,7 
Naturally occurring InvTCC in the dog is an excellent model of the disease in 
humans and has previously been used in the study of the injectable demethylating agent 
5-Aza-CR with promising results.8,9  The purpose of this study was to perform a phase I 







4.4 Materials and Methods 
Study subjects 
All work in pet dogs was approved by the Purdue Animal Care and Use 
Committee.  Privately owned dogs with a histopathological diagnosis of invasive 
transitional cell carcinoma undergoing treatment at the Purdue University Veterinary 
Teaching Hospital (PUVTH) was enrolled following informed written pet owner consent.  
Entry criteria included a definitive diagnosis of InvTCC via histopathology, measurable 
disease and an expected survival time of at least eight weeks.  Dogs were allowed to 
enroll if they had failed other cancer therapy or if other cancer therapy had been declined 
for any reason.  Dogs that had previously been treated with non-steroidal anti-
inflammatory drugs (NSAIDs) and had documented evidence of cancer progression were 
allowed to continue on NSAIDs after starting zeb.  Dogs lived at home with their owners 
and were regularly evaluated at the PUVTH. 
 
Dog monitoring and evaluation 
Physical examination was scheduled at least monthly at the PUVTH and weekly 
at the dogs’ local veterinary hospitals.  Serial complete blood counts (CBC) were 
scheduled weekly and then biweekly, or more often at the discretion of the attending 
veterinarian based on observed toxicity.  Serial serum biochemistry panels were 
scheduled monthly, or more often at the discretion of the attending veterinarian based on 
observed toxicity.  All toxicity was graded using the Veterinary Cooperative Oncology 





Staging tests including three view thoracic radiographs and complete abdominal 
ultrasound were scheduled at eight-week intervals.  Ultrasound of the urinary tract using 
a previously published protocol was performed once every four weeks.11  Urinary bladder 
ultrasound was performed by a single operator (DWK) when the urinary bladder was 
distended to a similar volume as the previous exam.  Dogs were placed in right lateral 
recumbency, and measurements were recorded.  Bladder tumor volume was estimated by 
multiplying the lesion area in the sagittal plane by the dorsal-ventral dimension in the 
transverse plane measurement and sagittal plane measurement.11  Tumor response was 
defined as complete remission (CR) if there was complete resolution of all lesions, partial 
remission (PR) if there was ≥50% decrease in tumor volume but not complete resolution 
of all lesions, stable disease (SD) if there was <50% increase or decrease in tumor 
volume for at least eight weeks and progressive disease (PD) if a ≥50% increase in tumor 
volume was detected or new lesions developed.   
 
Zebularine peak and trough concentration 
After at least four weeks of zeb treatment, peak (two hours after an oral zeb dose 
with food) and trough (approximately 24 hours after the last zeb dose) blood samples 
were collected into ethylenediaminetetraacetic acid (EDTA) blood collection tubes and 
immediately centrifuged (1,800 g, 15 min, 4°C).  Plasma was collected and stored at -
80°C until analysis.  Analysis to determine the plasma zeb concentration was performed 
by the Clinical Pharmacology Analytical Core Facility at Indiana University School of 







Zeb was provided by the National Cancer Institute’s Experimental Therapeutics 
(NExT) Program as a bulk powder and compounded into gelatin capsules from 0.5 to 20 
mg by Diamondback Drugs, LLC (Scottsdale, AZ, USA). 
 
Zebularine dose escalation 
Pet dogs received an initial zeb dose of 0.2 mg kg-1 per day in food based on the 
data presented in Chapter 3.  Enrollment of a minimum of three dogs per cohort was 
planned with dose escalation of 0.1 mg kg-1 per cohort.  DLT was defined as any grade 3 
or greater adverse event as described by VCOG-CTCAE v1.11.10  Dose cohorts were 
expanded to include at least six dogs if a DLT was observed.  MTD was defined as the 
dose at which a DLT occurred in no more than one of six dogs within a cohort.  
Treatment with zeb was continued as long as there was evidence of disease control, 
defined as CR, PR or SD, was detected.  Dose escalation was allowed if there was 




A total of 26 dogs with InvTCC were enrolled in six treatment cohorts.  There 
were 17 female spayed dogs and nine male neutered dogs.  Median age was 11.6 years 
(range 6.8 to 17.3), and median weight was 17.5 kgs (range 3.8 to 36.7).  The most 
common breeds were mixed breed (n=5), Scottish Terrier (n=4), West Highland White 





represented by one dog each included Australian Shepherd, Basset Hound, Beagle, Collie, 
Dachshund, German Shepherd Dog, Golden Retriever, Labrador Retriever and Yorkshire 
Terrier.  Of the 26 dogs, 73% (n=19) had failed previous treatments including NSAIDs, 
oral chemotherapy and injectable chemotherapy. 
Two dose escalations were performed within one dog from 0.2 to 0.3 and then to 
0.4 mg kg-1 without evidence of PD.  Dose escalation was performed within one dog 
from 0.3 to 0.4 without evidence of PD.  Dose escalation was performed within one dog 
from 0.5 to 0.6 mg kg-1 due to PD.  Dose de-escalation was performed in one dog from 
0.3 to 0.2 mg kg-1 due to grade 1 neutropenia.  Patient characteristics for each treatment 
cohort are summarized in Table 4.1.   
 
Zebularine toxicity  
Hematologic toxicity is summarized in Table 4.2.  Grade 1 neutropenia (n=1) and 
grade 1 thrombocytopenia (n=1) were detected in the 0.2 mg kg-1 cohort.  Grade 1 
neutropenia (n=1) was detected in the 0.3 mg kg-1 cohort.  The dose of zeb in one dog 
was de-escalated to the 0.2 mg kg-1 cohort from the 0.3 mg kg-1 cohort, but grade 1 
neutropenia persisted.  Grade 1 neutropenia (n=1) and grade 2 thrombocytopenia (n=1) 
were detected in the 0.4 mg kg-1 cohort.  Grade 1 neutropenia (n=1) and grade 1 
thrombocytopenia (n=1) were detected in the 0.5 mg kg-1 cohort.  Grade 3 neutropenia 
(n=1), grade 1 neutropenia (n=1) and grade 2 thrombocytopenia (n=1) were detected in 





Grade 2 anorexia was reported in one dog in the 0.4 mg kg-1 cohort.  No other 
remarkable gastrointestinal adverse events were reported that were not present prior to 
starting zeb.  No remarkable changes were noted in serial serum biochemistry panels. 
One dog in the 0.3 mg kg-1 cohort with a history of seizures that were reportedly 
well controlled with potassium bromide had one seizure approximately 24 hours after the 
first dose of zeb.  Zeb was discontinued, but the dog had additional seizures.  An MRI 
was performed and revealed a T1 and T2 hypointense intra-axial mass within the left 
olfactory bulb with heterogeneous central contrast enhancement and strong peripheral 
contrast enhancement.  The appearance of this lesion was consistent with a meningioma. 
Several dogs enrolled in the 0.6 mg kg-1 cohort and the dog in the 0.7 mg kg-1 
cohort have been enrolled for less than eight weeks at the time of this analysis.  While no 
adverse events have been reported at the time of this analysis, these dog may not have 
been enrolled for long enough to detect adverse events. 
 
Tumor response 
Of 26 individual dogs, 19 dogs have been evaluable for tumor response after at 
least eight weeks of therapy.  No complete or partial remissions were detected.  SD was 
detected in 14 dogs (73.7%), and PD was detected in 5 dogs (26.3%).  Overall disease 
control rate, defined as CR, PR or SD was 73.7%.  Dogs were excluded from evaluation 
of tumor response if there was no evidence of tumor progression but dogs had been on 
treatment for less than eight weeks (n=3) or if they had stopped zeb for any reason other 
than tumor progression (n=4).  One dog stopped zeb after one dose due to seizures.  





after 40 days of zeb treatment without evidence of tumor progression due to acute hind 
limb paresis due to suspected intervertebral disc disease (IVDD).  IVDD was confirmed 
at necropsy.  One dog with a history of syncopal episodes and pancreatitis died acutely at 
home after 10 days of treatment.  A necropsy was declined in this case.  One dog with a 
history of marked anorexia prior to starting zeb treatment stopped treatment after 22 days. 
Progression free survival analysis was performed using IBM’s SPSS Statistics 21.  
Dogs were censored from survival analysis if they were still alive and on zeb at the time 
of analysis (n=7), if zeb was stopped for any reason other than disease progression (n=4) 
or if they were lost to follow up (n=1).  Median progression free survival calculated using 
the Kaplan Meier product limit was 86 days (95% CI, 47.5-124.5; see Figure 1). 
At the time of analysis, two dogs have experienced ongoing long-term disease 
stabilization.  One dog experiencing SD for more than 511 days has had the dose 
escalated without progressive disease from 0.2 to 0.3 and then 0.4 mg kg-1.  One dog 
experiencing SD for more than 182 days was treated at 0.4 mg kg-1. 
 
Zebularine peak and trough plasma concentrations 
Peak and trough plasma samples following at least four weeks of daily zeb 
treatment were available from dogs treated daily with 0.2 mg kg-1 (n=6), 0.3 mg kg-1 (n=7) 
and 0.4 mg kg-1 (n=1).  Following daily oral zeb treatment with 0.2, 0.3 and 0.4 mg kg-1, 
mean zeb peak plasma concentrations were 179 ± 50 ng ml-1 (0.78 ± 0.22 µM), 233 ± 131 
ng ml-1 (1.1 ± 0.57  µM) and 292 ng ml-1 (1.28 µM), respectively.  Following daily oral 





64 ± 17 ng ml-1 (0.28 ± 0.075 µM), 101 ± 40 ng ml-1 (0.44 ± 0.17 µM) and 67 ng ml-1 
(0.29 µM), respectively. 
 
4.6 Discussion 
The purpose of this phase I trial was to determine the DLT and MTD of daily oral 
zeb in dogs with InvTCC.  Naturally occurring InvTCC in the dog is a relevant model of 
human cancer, and discoveries in the dog can be translated into more effective treatments 
in humans.  Globally, 2.1% of all human cancer deaths are attributed to bladder cancer.12  
Demethylating agents like 5-Aza-CR and 5-Aza-CDR are FDA approved for 
myelodysplastic syndrome,2,5 and these agents are being investigated in the treatment of 
solid tumors.6  Zeb was the first agent that resulted in successful demethylating activity 
following oral administration.1 
Overall, zeb was well tolerated in dogs with InvTCC up to 0.5 mg kg-1.  Based on 
previous work by our group, hematologic toxicity was anticipated as dose increased (see 
Chapter 3).  A DLT of grade 3 neutropenia was detected in one dog within the 0.6 mg kg-
1 cohort.  MTD was defined as the cohort in which one of six dogs experienced a DLT.  
By definition, MTD has not yet been reached at the time of this analysis.  Based on 
toxicity that has been observed thus far, it is likely that 0.5 mg kg-1 will be the MTD for 
daily administration.  Further information will be provided as dogs within the 0.5, 0.6 and 
0.7 mg kg-1 cohorts continue to be evaluated. 
While tumor response was not a primary outcome, the overall disease control rate 
of 73.3% and median progression free survival of 86 days were promising.  Given the 





when the data is more mature is indicated.  Investigation of the DNA methylation 
patterns in responders and non-responders may reveal a subset of patients that are more 
likely to respond to demethylating therapy.  Of particular interest are 2 dogs with ongoing 
responses of 511 and 182 days. 
Measurement of zeb plasma concentrations following chronic daily oral 
administration revealed that zeb was present in the plasma at detectable levels throughout 
a 24-hour period.  The peak plasma concentrations of zeb were 179 ± 50 ng ml-1 (0.78 ± 
0.22 µM), 233 ± 131 ng ml-1 (1.1 ± 0.57  µM) and 292 ng ml-1 (1.28 µM) following daily 
oral dosing of 0.2, 0.3 and 0.4 mg kg-1, respectively.  The plasma zeb concentration 
achieved following treatment with daily 0.5 mg kg-1 is likely greater than 1 µM.  While 
these concentrations are far lower than concentrations previously investigated in vitro and 
in vivo, growing evidence suggests that such high concentrations may not be necessary 
for efficacy.  Treatment of human hematopoietic and epithelial cancer cell lines and 
derivative mouse xenografts with nanomolar doses of either 5-Aza-CR or 5-Aza-CDR 
resulted in altered gene expression and DNA demethylation.  At ultra low doses, 5-Aza-
CR and 5-Aza-CDR appear to target stem-like populations within tumors.  A stem-like 
population of cells would have to be depleted before a clinical response would be 
observed, which could account for the observed delay between treatment initiation and 
tumor response in humans with myelodysplastic syndrome.13  Zeb plasma concentrations 
in the micromolar or nanomolar range are safely achievable in the dog and these 






In summary, daily treatment with zeb up to 0.5 mg kg-1 has been well tolerated in 
dogs with InvTCC and resulted in a promising disease control of 73.3%.  Based on initial 
data analysis, the DLT of daily oral zeb is likely neutropenia at doses higher than 0.5 mg 
kg-1, and MTD is likely to be 0.5 mg kg-1.  A daily dose of zeb up to 0.5 mg kg-1 is a 
rational starting point for investigating the potential of zeb in combination with other 
cytotoxic chemotherapy agents. 
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Figure 4.1. Progression free survival for 26 dogs treated with invasive 
transitional cell carcinoma treated with zebularine.  Median progression free 
survival calculated using the Kaplan Meier product limit was 86 days (95% CI, 47.5-
124.5).  Dogs were censored (open squares) if they were still alive and on zeb at the 
time of analysis (n=7), if zeb was stopped for any reason other than disease 
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CHAPTER 5.  CONCLUSION 
5.1 Conclusion 
 
Work published to date in rodents suggested that chronic zebularine (zeb) 
administration was well tolerated.  Limited information was available on the toxicity of 
zeb in animals larger than rats and suggested that zeb may be hepatotoxic.  This thesis 
presented the findings of the first investigation of zeb in dogs.  Initial pharmacokinetics 
in laboratory dogs (n=3) and tumor bearing dogs (n=3) revealed that zeb undergoes 
constant clearance in the dog.  High dose daily zeb (4 mg kg-1) resulted in remarkable but 
reversible neutropenia in laboratory dogs (n=3).  High dose intermittent zeb (4 mg kg-1 
once every 21 days) was well tolerated in tumor bearing dogs with no appreciable 
toxicity.  Based on the results of the initial pharmacokinetics and toxicity study, a phase I 
dose escalation trial of zeb was initiated in dogs with InvTCC at a daily starting dose of 
0.2 mg kg-1.  Low dose zeb was well tolerated at daily doses of up to 0.5 mg kg-1, but 
dose-limiting toxicity (DLT) in the form of neutropenia was detected at daily doses of 0.6 
mg kg-1.  Although evaluation of tumor response was not a primary goal of this study, the 
disease control rate and median progression free survival was detected in dogs with 
invasive transitional cell carcinoma (InvTCC). 
 High dose daily zeb resulted in unexpected and remarkable neutropenia in 






cynomolgus monkeys, remarkable neutropenia was not a feature of zeb toxicity 
that had been described.   The mechanism for neutropenia is unknown, but may reflect a 
cytotoxic effect that can be seen when demethylating agents are used at high doses.  The 
toxicity mirrored that which is seen following treatment with traditional cytotoxic 
chemotherapy as the most rapidly dividing granulocyte precursors appeared to be most 
affected.  Importantly, this toxicity was reversible with supportive care.  The unexpected 
myelosuppression at high zeb doses necessitated significant dose reductions before 
enrolling dogs with InvTCC in a phase I trial of low dose daily zeb. 
 Low dose daily zeb was well tolerated up to doses of 0.5 mg kg-1.  At 0.6 
mg kg-1, DLT in the form of grade 3 neutropenia was detected.  At the time of analysis, 
only one dog had demonstrated a grade 3 neutropenia, so maximum tolerated dose (MTD) 
was not reached as defined in the study.  As more dogs in the higher dose cohorts are 
evaluated, further toxicity may be identified.  A total of 26 dogs with InvTCC were 
treated with low dose daily zeb.  Of these 26 dogs, 19 were evaluable for tumor response.  
A disease control rate of 73.7% in a cohort of dogs that had been heavily pretreated is 
impressive.  Furthermore, one dog has experienced remarkable stable disease beyond 511 
days at the time of data analysis.  These results support that low dose oral zeb is a 
promising therapy for the treatment of InvTCC in the dog.  As the dog is a relevant model 
of human InvTCC, this work supports further investigation of zeb’s potential in humans. 
While a clear benefit following daily low dose zeb treatment was demonstrated in 
dogs with InvTCC, future research should be directed at confirming that this benefit is a 






in canine InvTCC.  A variety of canine InvTCC cell lines are readily available and may 
serve as an important tool to screen for gene specific methylation patterns that could then 
be used to target the investigation of methylation patterns in tumor samples from dogs 
and humans with InvTCC.  Necropsy is a useful tool for banking large amounts of normal 
tissue from dogs unaffected by cancer and dogs that have naturally occurring cancer for 
use in this type of study.  Exciting work has been performed in human clinical trials 
combining demethylating agents with cytotoxic chemotherapy and this is a next logical 
step that is currently undergoing pilot investigation at Purdue. 
In conclusion, high dose daily zeb results in an unacceptable level of neutropenia 
that was reversible.  A less frequent high dose of zeb was well tolerated.  As the optimal 
dosing strategy for demethylating agents is likely frequent administration, a phase I dose 
escalation trial of low dose oral zeb was performed.  Daily low dose zeb at doses up to 
0.5 mg kg-1 was well tolerated and resulted in promising disease control rates in dogs 
with InvTCC.  The work presented in this thesis supports further investigation of zeb in 
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! Hand-reared psittacines including macaws, cockatoos, Amazons, African Greys, 
hawkhead parrots, parakeets, lorikeets and lories 
 
Awards and Honors 
Dr. Ann L. Johnson and Walter E. Hoffmann Residency Teaching Award for 
outstanding teaching by a resident in the Department of Veterinary Clinical Sciences at 
Purdue University 
Recipient – April 2014 
Veterinary Cancer Society E. Gregory MacEwen Memorial Award for outstanding 
oral abstract presentation of research in basic science 
Recipient – April 2013 
Veterinary Cancer Society Senior Student Award for interest/excellence in oncology 
Recipient – Spring 2010 
Central Indiana Veterinary Medical Association Award for outstanding 
communication skills 
Recipient – Spring 2010 
Veterinary Pet Insurance/VBMA Case Study Competition  
PVM Chapter Winner – Spring 2010 
J.E. Salsbury Scholarship for leadership, academic success, initiative and perseverance 
Recipient – Fall 2009 
Phi Zeta 1st Place Research Award for Third-Year Veterinary Students 
Recipient – Spring 2009 
Holly Watts Memorial Award for interest/proficiency in treatment/care of exotic pets 
Recipient – Spring 2009 




Recipient – Fall 2008 
Veterinary Software Associates Veterinary Learning Award for academics/leadership 
Recipient – Spring 2008 
Indiana Top Resident Scholarship for outstanding academic performance 
Recipient – August 2001 to August 2005 
Purdue University President’s Leadership Class selected for leadership potential 
Member – Fall 2001 to Spring 2002 
 
Research Experience 
Purdue University College of Veterinary Medicine 
Thesis Master’s and Resident Projects – Fall 2011 to July 2014 
! Pharmacokinetics and toxicity of zebularine, an oral demethylating agent, in normal 
and tumor bearing dogs 
! Evaluation of the combination of zebularine and chemotherapy drugs in vivo in dogs 
with transitional cell carcinoma 
! Administration of carboplatin as a rescue agent for high grade canine lymphoma 
Texas A&M College of Veterinary Medicine and Biomedical Sciences 
Intern Project – Fall 2010 to Spring 2011 
! The role of vascular endothelial growth factor expression in canine InvTCC 
Purdue University Veterinary Teaching Hospital 
Anesthesia Research Assistant – January 2009 to February 2009 
! Assisted with a study on the efficacy of transmucosal buprenorphine administration 
for analgesia in dogs during the first 24 hours following spay or castration 
! Performed regular physical exams, pain assessment and blood collection on research 
subjects 
Surgical Assistant for DNR Rattlesnake Project – Summer 2009 
! Assisted PUVTH faculty with radiotransmitter implantation in timber rattlesnakes 
! Radiotransmitters were used to collect data on rattlesnake snake movements and 
habitats in southern Indiana and study the impact of human development on the 
rattlesnake population 
! Anesthetized snakes using isoflurane, administered antibiotics, administered 
analgesics and monitored snakes during induction, surgery and recovery 
Merck-Merial Summer Research Program 
Research Fellow – Summer 2007 and Summer 2008 
! Investigated the role of the protein LYAR in oncogenesis by developing a knock-out 
by gene-trap insertion mouse model that under-expressed the protein and a transgenic 
mouse model that over-expressed the protein 
! Practiced a variety of laboratory techniques including PCR, electrophoresis, Western 
blot, immunoprecipitation, flow cytometry, radioimmunoassay, cell culture and 
mouse husbandry 
! Wrote an abstract and created a poster to present research findings at local events and 
during the Merck-Merial Summer Research Symposium held at the National 
Institutes of Health in 2007 and Michigan State University in 2008 





Purdue University College of Liberal Arts Honors Colloquium 
Presenter – Spring 2002 
! Presented the findings of an original research paper, the culminating project of an 
honors research seminar on politics, social groups and the media, that explored the 
role of race in newspaper coverage of political scandals 
Purdue University College of Liberal Arts Freshman Dean’s Scholar Program 
Participant – Fall 2001 to Spring 2002 
! Assisted with a project studying the role of cholecystokinin (CCK) and the vagus 
nerve in hunger satiety using mouse and rat models 
! A partial or complete vagal transection was performed on experimental subjects while 
controls received no surgery or a sham surgery; CCK was administered to all subjects 
via an intraperitoneal injection and post-injection glucose consumption was recorded 
! Practiced restraint of mice and rats, injection techniques, collected data and 
maintained mechanized feeding and watering equipment 
 
Grants 
Veterinary Clinical Sciences Graduate Student Competitive Research Fund 
Purdue University College of Veterinary Medicine – awarded December 2012 
! Pilot study assessing the combination of a novel demethylating agent and carboplatin 
for more effective treatment of invasive bladder cancer 
Peer-reviewed Publications 
1. Fulkerson CM, Dhawan D, Jones DR, Fourez LM, Bonney PL and Knapp DW. 
Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in 
laboratory and tumor bearing dogs. 2014; Manuscript in progress. 
2. Wang G, Fulkerson CM, Malek R, Ghassemifar S, Snyder PW, & Mendrysa SM.  
Mutations in Lyar and p53 are synergistically lethal in female mice.  Birth Defects 
Res A Clin Mol Teratol. 2012; 94:729-737. 
3. Cichocki B, Robarge M, Fulkerson CM, Scott-Moncrieff JC, & Ramos-Vara J.  
Multiple endocrine neoplasia-like syndrome in an 11-year-old dog with concurrent 




VM 83000 Applications & Integrations II 
January to February 2013 
! Served as a tutor for 1st year veterinary students in a problem-based learning course 
VCS 22600 Principles of Veterinary Anesthesia Lab 
February 2012 
! Laboratory instructor for veterinary technology students learning how to perform 
general anesthesia and dentistry procedures 
VCS 84500 Small Animal Medicine Lab 
Fall 2011 and Fall 2012 
! Laboratory instructor for 3rd year veterinary students learning how to perform bone 




VCS 87102 Oncology (Clinical Rotation) 
Summer 2011 to present 
! Responsibilities include leading student topic rounds, working one-on-one with 4th 
year veterinary students to develop diagnostic and treatment plans for oncology 
referral cases and teaching biopsy and other diagnostic techniques to 4th year students 
and house officers 
VCS 86100/87100 Small Animal Medicine I & II (Clinical Rotation) 
January 2012 
! Worked one-on-one with 4th year veterinary students to develop diagnostic and 
treatment plans for internal medicine referral cases 
 
Presentations 
American College of Veterinary Medicine Forum 2014 
Pharmacokinetics and Toxicity of the Novel Oral Demethylating Agent Zebularine in 
Laboratory Dogs and Dogs With Transitional Cell Carcinoma – June 2014 
! Selected as one of 2 presenters to present a 12 minute oral abstract originally 
presented at Veterinary Cancer Society Annual Meeting; reporting on 
pharmacokinetics and toxicity data in laboratory and tumor bearing dogs treated with 
the oral demethylating agent zebularine and preliminary results of a phase 1 dose-
escalating trial in dogs with transitional cell carcinoma 
Veterinary Cancer Society Annual Meeting  
Pharmacokinetics and Toxicity of the Novel Oral Demethylating Agent Zebularine in 
Laboratory Dogs and Dogs With Transitional Cell Carcinoma – October 2013 
! Presented 12 minute oral abstract reporting on pharmacokinetics and toxicity data in 
laboratory and tumor bearing dogs treated with the oral demethylating agent 
zebularine and preliminary results of a phase 1 dose-escalating trial in dogs with 
transitional cell carcinoma 
Purdue Veterinary Medicine Phi Zeta Day 2013 
Pharmacokinetics and Toxicity of the Novel Oral Demethylating Agent Zebularine in 
Laboratory and Tumor bearing Dogs – April 2013 
! Presented poster with initial pharmacokinetics and toxicity data in laboratory and 
tumor bearing dogs treated with the oral demethylating agent zebularine 
Purdue University Comparative Oncology Program Research Meeting 
Epigenetics: A Primer – January 2013 
! Presented a 50-minute review for the PCOP faculty and staff on genetics and 
epigenetic changes in cancer (with an emphasis on the current literature on DNA 
methylation, histone modifications and microRNAs) 
Purdue University Veterinary Clinical Sciences Departmental Seminar 
Pharmacokinetics and Toxicity of the Novel Oral Demethylating Agent Zebularine in 
Laboratory Dogs and Dogs With Transitional Cell Carcinoma – September 2013 
! Presented 12 minute oral abstract reporting on pharmacokinetics and toxicity data in 
laboratory and tumor bearing dogs treated with the oral demethylating agent 
zebularine and preliminary results of a phase 1 dose-escalating trial in dogs with 





Diagnosing and Treating Canine Lymphoma – October 2012 
! Presented a 50-minute seminar reviewing lymphoma in the dog with an emphasis on 
the importance and prognostic significance of a specific histopathologic diagnosis in 
this disease; introduced an on-going clinical trial using carboplatin as a rescue agent 
for dogs with relapsed diffuse large B-cell lymphoma 
Epigenetics and Cancer – April 2012 
! Presented a 50-minute seminar introducing the topic of epigenetics with an emphasis 
on the use of demethylating agents in dogs with transitional cell carcinoma; 
introduced zebularine, a demethylating agent zebularine that is under clinical 
investigation in the dog 
Purdue University Veterinary Teaching Hospital Histopathology Rounds 
A Dachshund With a Multitude of Tumors – October 2012 
! Presented a 20 minute clinical case presentation of a dachshund treated at the PUVTH 
for oral malignant melanoma and multiple cancers in endocrine organs in association 
with a presentation of pertinent histopathologic findings by an anatomic pathology 
resident 
Telangiectactic Osteosarcoma (?) in the Rib of a Dog – October 2013 
! Presented a 20 minute clinical case presentation of a mastiff-mix treated at the 
PUVTH for a rib tumor that was initially diagnosed as a telangiectatic osteosarcoma 
in association with a presentation of pertinent histopathologic findings by an 
anatomic pathology resident 
Purdue University Veterinary Teaching Hospital Intern Rounds 
Mast Cell Tumors – February 2013 
! Presented a 50-minute update on canine mast cell tumors that incorporated a critical 
review of recent peer-reviewed literature using ancillary diagnostic tests to guide 
treatment recommendations 
Principles of Chemotherapy – February 2012 
! Presented a 50-minute introduction to the principles for using cytotoxic chemotherapy 
drugs, common drugs used in the clinic and managing relevant toxicity in the context 
of the emergency room 
Texas A&M College of Veterinary Medicine Resident and Intern Seminar Series 
VEGFR Expression in Canine Transitional Cell Carcinoma – May 2011 
! Presented a 25-minute seminar introducing the topic of canine transitional cell 
carcinoma including diagnosis, treatment and prognosis, and reported on the results 
of a retrospective evaluation of immunohistochemical staining for vascular 
endothelial growth factor receptor in tissues obtained from dogs with transitional cell 
carcinoma at the time of necropsy 
 
Continuing Education 
American College of Veterinary Medicine Forum 2014 
Attendee and oral abstract presenter – Nashville, TN; June 2014 
Veterinary Cancer Society Annual Meeting  
Attendee and oral abstract presenter – Minneapolis, MN; October 2013 
Clinician Scientist Training Workshop 




Purdue University Center for Cancer Research/Indiana University Simon Cancer 
Center Bladder Cancer Minisymposium 
Attendee – Indianapolis, IN; March 2013 
Veterinary Cancer Society and ACVR Annual Meeting 
Attendee – Las Vegas, NV; October 2012 
American Association for Cancer Researchers Annual Meeting 
Attendee – Chicago, IL; March 2012 
3rd Annual Dentistry for Small Animal Practitioners & Technicians Conference 
Laboratory Instructor – College Station, TX; July 2010 
! Instructor for a four hour hands-on wet lab covering regional anesthesia techniques 
for use in dental procedures in the dog and cat 
Attendee – College Station, TX; July 2010 
! Attended eight hours of discussion and lectures on dental conditions and procedures 
applicable to primary care veterinary practice 
Purdue University Annual Fall Conference for Veterinarians and Veterinary 
Technicians 
Attendee – September 2007, 2008, 2009, 2011 and 2012 
Student American Veterinary Medical Association Symposium 
Attendee – The Ohio State University; March 2009 
Attendee – Auburn and Tuskegee Universities; March 2008 
Attendee – North Carolina State University; March 2007 
Merck-Merial Summer Research Symposium 
Attendee – Michigan State University; August 2008 
Attendee – National Institutes of Health; August 2007 
! Presented original research as part of the Merck-Merial Summer Research Program 
and attended lecture series on cutting edge veterinary, comparative and translational 
research 
6th Annual Veterinary Student Exotic Animal Symposium 
Attendee – University of Tennessee; January 2008 
 
Veterinary Study Abroad Experience 
Introduction to Conservation Medicine in South Africa 
Participant – May 2008 
! Studied immobilization techniques, anesthetic drugs, field necropsy techniques and 
management strategies for communicable wildlife diseases in South Africa 
! Practiced capture and immobilization techniques, intravenous catheter placement and 
sedation monitoring in giraffe, white rhinoceros and African hoofstock including cape 
buffalo, impala, kudu and wildebeest 
! Performed screening tests on captive hoofstock for infectious diseases including 
theileriosis, tuberculosis and foot and mouth disease 
 
Organizations and Leadership Activities  
Phi Zeta, Omicron Chapter 





Alternate Graduate Student Representative to the PVM Grade Appeals Committee 
November 2013 to July 2014 
Purdue Veterinary Teach Hospital Continual Improvement Committee 
October 2013 to present 
Resident Representative to Purdue University Veterinary Clinical Sciences Faculty 
September 2012 to July 2014 
Veterinary Centers of America (VCA) 
Senior Student Representative – July 2009 to May 2010 
Student Representative – July 2008 to July 2009 
Purdue University CVM Student-Faculty Liaison Committee 
Student Member – Spring 2009 to Spring 2010 
Purdue University CVM 50th Anniversary Executive Committee 
Student Events Committee Co-Chair – Spring 2008 to Fall 2009 
Omega Tau Sigma, Xi Chapter 
President – Spring 2007 to Spring 2009 
Grand Council Delegate  – Fall 2006, Fall 2007 and Fall 2008 
Member – Fall 2006 to Spring 2010 
! As President, created a Philanthropy chair position to coordinate philanthropic 
activities and encourage community involvement by veterinary students; teamed with 
other student organizations for large scale projects for the local community and a 
national project for Heifer International 
! Worked to promote unity within the PVM by planning social events that brought 
together the entire PVM community including veterinary students, veterinary 
technology students, faculty and staff 
Student Chapter of the American Veterinary Medical Association (SCAVMA) 
Budget and Documents Committee Member – Spring 2008 to Spring 2009 
Executive Board Member – Spring 2007 to Spring 2009  
Member – Fall 2006 to Spring 2010 
Veterinary Business Management Association (VBMA) 
Marketing Director – Spring 2007 to Fall 2007 
Member – Fall 2006 to Spring 2010 
Exotics Club 
Member – Fall 2006 to Spring 2010 
International Veterinary Student Association (IVSA) 
Member – Fall 2006 to Spring 2010 
Student Veterinary Emergency and Critical Care Society (SVECCS) 
Member – Fall 2006 to Spring 2010 
Purdue University College of Liberal Arts Dean’s Ambassadors 
Ambassador – Fall 2002 to Spring 2006 
Alpha Lambda Delta and Phi Eta Sigma Undergraduate Honor Society 
Senior Advisor – Spring 2003 to Spring 2004 
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PL and Knapp DW. Pharmacokinetics and toxicity of the novel oral demethylating 
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